Entrada Therapeutics (TRDA) Other Non-Current Assets (2020 - 2026)

Entrada Therapeutics' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 1277.41% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $3.3 million, a 1277.41% increase from a year earlier, with the FY2025 full-year figure at $70000.0, down 75.35% from the prior year.
• Other Non-Current Assets rose to $3.3 million in Q1 2026 per TRDA's latest filing, from $70000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $13.8 million in Q1 2023 and bottomed at $70000.0 in Q4 2025.
• The 5-year median for Other Non-Current Assets is $3.3 million (2026), against an average of $2.9 million.
• Across the five-year window, Other Non-Current Assets sank 95.87% in 2025 and soared 1277.41% in 2026, its largest moves.
• Year by year, Other Non-Current Assets stood at $4.0 million in 2022, then fell by 29.37% to $2.8 million in 2023, then tumbled by 89.82% to $284000.0 in 2024, then plunged by 75.35% to $70000.0 in 2025, then jumped by 4602.86% to $3.3 million in 2026.
• Per Business Quant, the three latest TRDA Other Non-Current Assets figures stand at $3.3 million (Q1 2026), $70000.0 (Q4 2025), and $163000.0 (Q3 2025).